PSI Sci
New here? Follow the money and the votes · Not sure of your district? Find your U.S. House member · Find your state legislators

H.R. 7506: New Era of Preventing End-Stage Kidney Disease Act

Before you vote › Federal bills

H.R. 7506: New Era of Preventing End-Stage Kidney Disease Act

117th Congress · introduced 2022-04-14 · Health · Latest: Referred to the Subcommittee on Health.

federal

Follow this bill, step by step

  1. Where it came from: introduced 2022-04-14 · official record
  2. Who proposed it: Rep. Butterfield, G. K. [D-NC-1] · what a sponsor is
  3. What happened next: no floor votes in our records yet. Why?
  4. Where it stands now: Referred to the Subcommittee on Health. Not final yet: this can still change. We check for updates every day.
  5. If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

New Era of Preventing End-Stage Kidney Disease Act

Plain summary

New Era of Preventing End-Stage Kidney Disease Act This bill addresses rare kidney diseases through research, training for health professionals, and other means. It also modifies requirements for Medicare drug plan formularies that include drugs for rare diseases or conditions. The Department of Health and Human Services (HHS) must convene a conference focused on diagnosis and treatment of rare kidney diseases; study risk factors, access to care (including to genetic and genomic testing), and other matters related to rare kidney diseases; and establish grants for supporting kidney disease education and referrals in communities of color. HHS may award grants to educate and train health professionals about kidney disease and nephrology. Additionally, health professional schools that receive certain HHS funding for educating underrepresented minority individuals must support postgraduate nephrology training. The National Institutes of Health (NIH) must report on diversity in its kidney disease research. The NIH may also (1) support research on rare kidney diseases that, among other requirements, includes persons of color in study populations; and (2) establish regional centers of excellence for rare kidney diseases. The Centers for Medicare & Medicaid Services must evaluate methods for (1) treating rare kidney diseases, with a focus on delaying dialysis and transplant; and (2) raising awareness about rare kidney diseases, including in communities of color. Furthermore, if a Medicare drug plan formulary includes a drug to treat a rare disease or condition, at least two members of the committee that develops or reviews the formulary must have expertise in the field of medicine related to that drug.

Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

New Era of Preventing End-Stage Kidney Disease Act

Source: Congressional Research Service summary (Introduced in House)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Butterfield, G. K. [D-NC-1] · 13 cosponsors

Cost estimate: No cost estimate published yet.

Cosponsors on this site

Gus M. Bilirakis (R-FL), Sanford D. Bishop, Jr. (D-GA), Mike Levin (D-CA), Deborah K. Ross (D-NC), Zoe Lofgren (D-CA), Scott H. Peters (D-CA), Danny K. Davis (D-IL), Dan Crenshaw (R-TX)

No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.

Words on this page, explained (1)
Bill
A proposed law. It becomes law only if it passes the legislature and is signed by the president or governor (or a veto is overridden).

Plain meanings written from linked sources. All words.

Sources

Record fed-us-cong117-hr7506 · catalog fed-us-congress-bills-cong117 · updated 2026-11-15 by psicol fed-bills-cong117